Clinical characteristics
| Variables | Development cohort N=1107 | Validation cohort N=1108 | P value |
| Age, years | 75 (69, 80) | 75 (69, 80) | 0.723 |
| Male | 870 (78.6) | 881 (79.5) | 0.594 |
| BMI, kg/m2 | 24.2 (22.2, 26.6) | 24.2 (22.2, 26.5) | 0.782 |
| Systolic BP, mm Hg | 126 (116, 136) | 126 (116, 135) | 0.722 |
| Diastolic BP, mm Hg | 70 (64, 78) | 71 (64, 80) | 0.350 |
| Current smoker | 149 (13.5) | 143 (12.9) | 0.700 |
| Alcohol consumption | 0.369 | ||
| Daily | 202 (18.2) | 221 (19.9) | |
| Occasionally | 361 (32.6) | 374 (33.8) | |
| None | 544 (49.1) | 513 (46.3) | |
| Rivaroxaban monotherapy | 549 (49.6) | 558 (50.4) | 0.718 |
| Dose of rivaroxaban | 0.459 | ||
| 10 mg/day | 509 (46.0) | 501 (45.2) | |
| 15 mg/day | 588 (53.1) | 596 (53.8) | |
| Other | 2 (0.2) | 0 (0.0) | |
| Unknown | 8 (0.7) | 11 (1.0) | |
| Type of atrial fibrillation | 0.337 | ||
| Paroxysmal | 571 (51.6) | 605 (54.6) | |
| Persistent | 172 (15.5) | 167 (15.1) | |
| Permanent | 364 (32.9) | 336 (30.3) | |
| Hypertension | 955 (86.3) | 936 (84.5) | 0.233 |
| Diabetes mellitus | 460 (41.6) | 467 (42.1) | 0.777 |
| Dyslipidaemia | 774 (69.9) | 764 (69.0) | 0.622 |
| Angina pectoris | 714 (64.5) | 696 (62.8) | 0.410 |
| Heart failure | 398 (36.0) | 390 (35.2) | 0.711 |
| Liver dysfunction | 19 (1.7) | 22 (2.0) | 0.638 |
| Creatinine clearance | 59.8 (45.7, 75.0) | 58.7 (44.8, 74.0) | 0.322 |
| Haemorrhagic diathesis | 17 (1.5) | 15 (1.4) | 0.720 |
| Prior stroke | 158 (14.3) | 165 (14.9) | 0.680 |
| Transient ischaemic attack | 23 (2.1) | 25 (2.3) | 0.773 |
| Prior myocardial infarction | 381 (34.4) | 396 (35.7) | 0.514 |
| Prior PCI | 779 (70.4) | 785 (70.8) | 0.805 |
| Stent implantation | 718 (64.9) | 726 (65.5) | 0.743 |
| Type of stent | 0.802 | ||
| Drug-eluting | 480/718 (66.9) | 497/726 (68.5) | |
| Bare-metal | 179/718 (24.9) | 163/726 (22.5) | |
| Both types | 27/718 (3.8) | 28/726 (3.9) | |
| Unknown | 32/718 (4.5) | 38/726 (5.2) | |
| Cipher | 86/718 (12.0) | 88/726 (12.1) | |
| TAXUS | 32/718 (4.5) | 23/726 (3.2) | |
| Endeavour | 23/718 (3.2) | 29/726 (4.0) | |
| Xience | 187/718 (26.0) | 201/726 (27.7) | |
| Promus | 103/718 (14.3) | 112/726 (15.4) | |
| Nobori | 46/718 (6.4) | 38/726 (5.2) | |
| Other | 67/718 (9.3) | 97/726 (13.4) | |
| Prior CABG | 128 (11.6) | 124 (11.2) | 0.783 |
| Location of culprit lesion | |||
| Segment #1 | 113 (10.2) | 127 (11.5) | 0.342 |
| Segment #2 | 134 (12.1) | 123 (11.1) | 0.461 |
| Segment #3 | 111 (10.0) | 106 (9.6) | 0.716 |
| Segment #4PD | 20 (1.8) | 33 (3.0) | 0.071 |
| Segment #4AV | 24 (2.2) | 36 (3.2) | 0.117 |
| Segment #5 | 15 (1.4) | 31 (2.8) | 0.017 |
| Segment #6 | 251 (22.7) | 258 (23.3) | 0.732 |
| Segment #7 | 253 (22.9) | 298 (26.9) | 0.028 |
| Segment #8 | 17 (1.5) | 34 (3.1) | 0.016 |
| Segment #9 | 43 (3.9) | 37 (3.3) | 0.492 |
| Segment #10 | 2 (0.2) | 4 (0.4) | 0.687 |
| Segment #11 | 77 (7.0) | 71 (6.4) | 0.606 |
| Segment #12 | 44 (4.0) | 29 (2.6) | 0.074 |
| Segment #13 | 117 (10.6) | 125 (11.3) | 0.591 |
| Segment #14 | 34 (3.1) | 34 (3.1) | 0.997 |
| Segment #15 | 15 (1.4) | 10 (0.9) | 0.313 |
| Interventions other than PCI or CABG | 120 (10.8) | 158 (14.3) | 0.015 |
| Prior aortic aneurysm | 46 (4.2) | 30 (2.7) | 0.061 |
| Systemic embolism | 5 (0.6) | 6 (0.5) | 0.764 |
| Deep venous thrombosis | 8 (0.7) | 6 (0.5) | 0.591 |
| Pulmonary embolism | 3 (0.3) | 5 (0.5) | 0.726 |
| Peripheral artery disease | 70 (6.3) | 69 (6.2) | 0.926 |
| Other ischaemic disorder | 87 (7.9) | 104 (9.4) | 0.200 |
| Prior bleeding complication | 37 (3.3) | 22 (2.0) | 0.047 |
| Proton pomp inhibitor | 670 (60.5) | 687 (62.0) | 0.475 |
| NSAIDs | 29 (2.6) | 16 (1.4) | 0.050 |
Data are presented as n (%) or median (IQR).
AV, atrioventricular branch; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; NSAIDs, nonsteroidal anti-inflammatory drugs; PCI, percutaneous coronary intervention; PD, posterior descending branch.